LANXESS completes acquisition of Brazilian biocide manufacturer IPEL

Specialty chemicals company LANXESS today, February 3, 2020, completed the acquisition of Itibanyl Produtos Especiais Ltda. (IPEL). The competent anti-trust authorities approved the transaction beginning of January.

IPEL with headquarters in Jarinu, São Paulo, is one of Brazil’s leading biocide manufacturers and generated sales in the lower double-digit million euro range in 2018. With the acquisition, LANXESS is strengthening its position as one of the world’s leading manufacturers of antimicrobial active ingredients and formulations. In addition to around 100 employees and the production facility, LANXESS has taken over the Brazilian company’s laboratory facilities.

IPEL generates the majority of its sales with biocides and specialty chemicals for the paint and coating industry. The product portfolio also includes preservatives and fungicides for process control in water treatment as well as active ingredients for disinfection and cleaning agents.


About LANXESS

LANXESS is a leading specialty chemicals company with sales of EUR 7.2 billion in 2018. The company currently has about 15,500 employees in 33 countries and is represented at 58 production sites worldwide. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. LANXESS is listed in the leading sustainability indices Dow Jones Sustainability Index (DJSI World and Europe) and FTSE4Good.

FORWARD-LOOKING STATEMENTS

 

This company release contains certain forward-looking statements, including assumptions, opinions, expectations and views of the company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or performance of LANXESS AG to differ materially from the estimations expressed or implied herein. LANXESS AG does not guarantee that the assumptions underlying such forward-looking statements are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this presentation or the actual occurrence of the forecast developments. No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, any information, estimates, targets and opinions, contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein, and accordingly, no representative of LANXESS AG or any of its affiliated companies or any of such person's officers, directors or employees accept any liability whatsoever arising directly or indirectly from the use of this document.